Noguchi A, Mukuria C J, Suzuki E, Naiki M
Department of Veterinary Science, National Institute of Health, Tokyo.
J Biochem. 1995 Jan;117(1):59-62. doi: 10.1093/oxfordjournals.jbchem.a124721.
Recombinant human erythropoietin (EPO) produced by Chinese hamster ovary cells and distributed by two different pharmaceutical companies were confirmed to contain about 1% N-glycolylneuraminic acid (Neu5Gc) in total sialic acid content. Since chickens, like humans, do not synthesize Neu5Gc, they were used to determine the immunogenicity of Neu5Gc epitope in EPO. Chickens immunized with EPO did not produce significant titer of antibody that was specific to GM3(Neu5Gc) as compared to antibody titers produced in chickens immunized with fetuin containing 7% Neu5Gc or GM3(Neu5Gc) containing 100% Neu5Gc. Results obtained by an ELISA inhibition test showed that EPO, compared to GM3(Neu5Gc), reacted almost one thousand times less strongly with a human Hanganutziu-Deicher (HD) antibody. This study implies that an increase of Neu5Gc content in a molecule enhances its HD antigenicity. The response to Neu5Gc in patients receiving therapeutic injections of EPO is currently under investigation.
由中国仓鼠卵巢细胞生产并由两家不同制药公司经销的重组人促红细胞生成素（EPO），经确认其总唾液酸含量中约含1%的N-羟乙酰神经氨酸（Neu5Gc）。由于鸡和人类一样不合成Neu5Gc，因此用鸡来测定EPO中Neu5Gc表位的免疫原性。与用含7%Neu5Gc的胎球蛋白或含100%Neu5Gc的GM3（Neu5Gc）免疫的鸡所产生的抗体效价相比，用EPO免疫的鸡未产生针对GM3（Neu5Gc）的显著抗体效价。酶联免疫吸附抑制试验的结果表明，与GM3（Neu5Gc）相比，EPO与人汉根纽齐乌-戴歇尔（HD）抗体的反应强度几乎低一千倍。这项研究表明，分子中Neu5Gc含量的增加会增强其HD抗原性。目前正在调查接受EPO治疗性注射的患者对Neu5Gc的反应。
